GILD Articles, Gilead Sciences Inc. - From 07/09/24

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.92% on an annualized basis producing an average annual return...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrade...

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...

These large-cap stocks were the best performers in the last week. Are they in your portfolio? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares incr...

Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...

Gilead Sciences, Inc. (NASDAQ:GILD) stock is moving higher Friday on continued strength following the company’s Phase 3 HIV data. What To Kno...

Thursday, Gilead Sciences Inc (NASDAQ:GILD) shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-ye...

U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Thursday. Shares of KB Home (NYSE:KBH) rose during Thursday's se...

Magrolimab was the centerpiece of Gilead Sciences Inc's (NASDAQ:GILD) $4.9 billion buyout of Forty Seven Inc in March 2020. Magrolimab is a mo...